DNA Diagnostics Market Size, Share & Trends by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Globa

DNA Diagnostics Market Size, Share & Trends by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029

The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period. Growth in the DNA diagnostics market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in DNA diagnostics for personalized medicine, and increasing funding by healthcare-based companies. Personalized medicines help in making informed clinical decisions and alleviating the risk of adverse events. Thus, the increasing demand for personalized medicines is expected to offer significant growth opportunities for players operating in the DNA diagnostics market in the coming years.

“The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period”

Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.

“The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period.”

Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.

“The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen”

Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.

“The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period”.

Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.

“The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user”.

Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.

“The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period”

The global DNA diagnostics market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America – 35%, Europe – 26%, Asia Pacific – 24%, Latin America – 12%, Middle East & Africa – 2%, and the GCC Countries – 1%

Lists of Companies Profiled in the Report:

Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).

Research Coverage:

In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).

The report's coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers: (Rising incidence of chronic and infectious diseases, Rising focus on R&D and increased funding by healthcare-based companies, Growing demand for early disease diagnosis an dpersonalized medicine in developing countries, and Technological advancements in DNA diagnostics industry), challenges (Changing regulatory landscape for IVD and DNA diagnostics in US and European Union, Operational barriers and shortage of skills across major markets, and Introductio of alternatives technologies for disease detection and diagnosis), opportunities (Growing significance of companion diagnostics in drug development process, Increasing growth opportunities for DNA diagnostic companies in emerging economies, Advancements in bioinformatics and artificial intelligence in DNA diagnostics and Expansion of direct-to-consumer (DTC) genetic tetsing), and restraints (Unfavourable reimbursement scenario for diagnostic companies, High cost of DNA diagnostic instruments, and Ethical and privacy concerns associated with DNA diagnosis) influencing the growth of the in DNA diagnostics market.

Product Development/Innovation: Detailed insights on research & development activities and new product launches and approvals in the DNA diagnostics market.

Market Development: Comprehensive information about lucrative markets – the report analyses the DNA diagnostics market across varied regions.

Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the DNA diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are among others, in the DNA diagnostics market strategies.